Market Access Capping the cost of insulin: altruistic or strategic? The price of insulin has become one of the most talked about issues across the pharma industry.
News Lilly shares disappointing A4 study results for solanezumab The drug only targets soluble amyloid beta-protein and doesn't clear amyloid plaques.
News Lilly slashes insulin price 70%, patient cost cap now $35 Lilly trying to make it easier for patients to access its insulin and help Americans generally.
R&D Almirall/Lilly lebrikizumab offers potential long-term manag... Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
